1
|
Specker E, Wesolowski R, Schütz A, Matthes S, Mallow K, Wasinska-Kalwa M, Winkler L, Oder A, Alenina N, Pleimes D, von Kries JP, Heinemann U, Bader M, Nazaré M. Structure-Based Design of Xanthine-Imidazopyridines and -Imidazothiazoles as Highly Potent and In Vivo Efficacious Tryptophan Hydroxylase Inhibitors. J Med Chem 2023; 66:14866-14896. [PMID: 37905925 DOI: 10.1021/acs.jmedchem.3c01454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2023]
Abstract
Tryptophan hydroxylases catalyze the first and rate-limiting step in the biosynthesis of serotonin, a well-known neurotransmitter that plays an important role in multiple physiological functions. A reduction of serotonin levels, especially in the brain, can cause dysregulation leading to depression or insomnia. In contrast, overproduction of peripheral serotonin is associated with symptoms like carcinoid syndrome and pulmonary arterial hypertension. Recently, we developed a class of TPH inhibitors based on xanthine-benzimidazoles, characterized by a tripartite-binding mode spanning the binding sites of the cosubstrate pterin and the substrate tryptophan and by chelation of the catalytic iron ion. Herein, we describe the structure-based development of a second generation of xanthine-imidiazopyridines and -imidazothiazoles designed to inhibit TPH1 in the periphery while preventing the interaction with TPH2 in the brain. Lead compound 32 (TPT-004) shows superior pharmacokinetic and pharmacodynamic properties as well as efficacy in preclinical models of peripheral serotonin attenuation and colorectal tumor growth.
Collapse
Affiliation(s)
- Edgar Specker
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
- Trypto Therapeutics GmbH, Robert-Rössle Straße 10, 13125 Berlin, Germany
| | - Radoslaw Wesolowski
- Trypto Therapeutics GmbH, Robert-Rössle Straße 10, 13125 Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Anja Schütz
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Susann Matthes
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Keven Mallow
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Malgorzata Wasinska-Kalwa
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Lars Winkler
- Experimental Pharmacology and Oncology GmbH, Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Andreas Oder
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Natalia Alenina
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Potsdamer Straße 58, 10785 Berlin, Germany
| | - Dirk Pleimes
- Trypto Therapeutics GmbH, Robert-Rössle Straße 10, 13125 Berlin, Germany
| | - Jens Peter von Kries
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Udo Heinemann
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Michael Bader
- Trypto Therapeutics GmbH, Robert-Rössle Straße 10, 13125 Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Potsdamer Straße 58, 10785 Berlin, Germany
- Charité─Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
- University of Lübeck, Institute for Biology, Ratzeburger Allee 160, 23562 Lübeck, Germany
| | - Marc Nazaré
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| |
Collapse
|
2
|
Specker E, Matthes S, Wesolowski R, Schütz A, Grohmann M, Alenina N, Pleimes D, Mallow K, Neuenschwander M, Gogolin A, Weise M, Pfeifer J, Ziebart N, Heinemann U, von Kries JP, Nazaré M, Bader M. Structure-Based Design of Xanthine-Benzimidazole Derivatives as Novel and Potent Tryptophan Hydroxylase Inhibitors. J Med Chem 2022; 65:11126-11149. [PMID: 35921615 DOI: 10.1021/acs.jmedchem.2c00598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Tryptophan hydroxylases catalyze the first and rate-limiting step in the synthesis of serotonin. Serotonin is a key neurotransmitter in the central nervous system and, in the periphery, functions as a local hormone with multiple physiological functions. Studies in genetically altered mouse models have shown that dysregulation of peripheral serotonin levels leads to metabolic, inflammatory, and fibrotic diseases. Overproduction of serotonin by tumor cells causes severe symptoms typical for the carcinoid syndrome, and tryptophan hydroxylase inhibitors are already in clinical use for patients suffering from this disease. Here, we describe a novel class of potent tryptophan hydroxylase inhibitors, characterized by spanning all active binding sites important for catalysis, specifically those of the cosubstrate pterin, the substrate tryptophan as well as directly chelating the catalytic iron ion. The inhibitors were designed to efficiently reduce serotonin in the periphery while not passing the blood-brain barrier, thus preserving serotonin levels in the brain.
Collapse
Affiliation(s)
- Edgar Specker
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany
| | - Susann Matthes
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany
| | - Radoslaw Wesolowski
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany
| | - Anja Schütz
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany
| | - Maik Grohmann
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany
| | - Natalia Alenina
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Potsdamer Str. 58, 10785 Berlin, Germany
| | - Dirk Pleimes
- SCINSPIRE Holding & Consulting GmbH, Dunckerstr. 25, 10437 Berlin, Germany
| | - Keven Mallow
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany
| | - Martin Neuenschwander
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany
| | - Angelina Gogolin
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany.,Berliner Hochschule für Technik (BHT), Luxemburger Str. 10, 13353 Berlin, Germany
| | - Marie Weise
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany.,Berliner Hochschule für Technik (BHT), Luxemburger Str. 10, 13353 Berlin, Germany
| | - Jochen Pfeifer
- Berliner Hochschule für Technik (BHT), Luxemburger Str. 10, 13353 Berlin, Germany
| | - Nandor Ziebart
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany.,Freie Universität Berlin, Chemistry and Biochemistry Institute, Takustr. 3, 14195 Berlin, Germany
| | - Udo Heinemann
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany.,Freie Universität Berlin, Chemistry and Biochemistry Institute, Takustr. 3, 14195 Berlin, Germany
| | - Jens Peter von Kries
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany
| | - Marc Nazaré
- Chemical Biology Platform, Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Rössle-Str.10, 13125 Berlin-Buch, Germany
| | - Michael Bader
- Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC), Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Potsdamer Str. 58, 10785 Berlin, Germany.,University of Lübeck, Institute for Biology, Ratzeburger Allee 160, 23562 Lübeck, Germany.,Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
| |
Collapse
|
3
|
Sidorova M, Kronenberg G, Matthes S, Petermann M, Hellweg R, Tuchina O, Bader M, Alenina N, Klempin F. Enduring Effects of Conditional Brain Serotonin Knockdown, Followed by Recovery, on Adult Rat Neurogenesis and Behavior. Cells 2021; 10:3240. [PMID: 34831469 PMCID: PMC8618971 DOI: 10.3390/cells10113240] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Revised: 11/14/2021] [Accepted: 11/16/2021] [Indexed: 01/31/2023] Open
Abstract
Serotonin (5-hydroxytryptamine, 5-HT) is a crucial signal in the neurogenic niche of the hippocampus, where it is involved in antidepressant action. Here, we utilized a new transgenic rat model (TetO-shTPH2), where brain 5-HT levels can be acutely altered based on doxycycline (Dox)-inducible shRNA-expression. On/off stimulations of 5-HT concentrations might uniquely mirror the clinical course of major depression (e.g., relapse after discontinuation of antidepressants) in humans. Specifically, we measured 5-HT levels, and 5-HT metabolite 5-HIAA, in various brain areas following acute tryptophan hydroxylase 2 (Tph2) knockdown, and replenishment, and examined behavior and proliferation and survival of newly generated cells in the dentate gyrus. We found that decreased 5-HT levels in the prefrontal cortex and raphe nuclei, but not in the hippocampus of TetO-shTPH2 rats, lead to an enduring anxious phenotype. Surprisingly, the reduction in 5-HT synthesis is associated with increased numbers of BrdU-labeled cells in the dentate gyrus. At 3 weeks of Tph2 replenishment, 5-HT levels return to baseline and survival of newly generated cells is unaffected. We speculate that the acutely induced decrease in 5-HT concentrations and increased neurogenesis might represent a compensatory mechanism.
Collapse
Affiliation(s)
- Maria Sidorova
- School of Life Sciences, Immanuel Kant Baltic Federal University, 236041 Kaliningrad, Russia; (M.S.); (O.T.)
- Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany; (S.M.); (M.P.); (M.B.); (N.A.)
| | - Golo Kronenberg
- Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatrische Universitätsklinik, 8032 Zürich, Switzerland;
- Department of Psychiatry and Psychotherapy, Charité University Medicine, 10117 Berlin, Germany;
| | - Susann Matthes
- Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany; (S.M.); (M.P.); (M.B.); (N.A.)
| | - Markus Petermann
- Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany; (S.M.); (M.P.); (M.B.); (N.A.)
- Department of Clinical Pharmacy and Pharmacotherapy, Institute of Pharmacy, Martin Luther University, 06120 Halle, Germany
| | - Rainer Hellweg
- Department of Psychiatry and Psychotherapy, Charité University Medicine, 10117 Berlin, Germany;
| | - Oksana Tuchina
- School of Life Sciences, Immanuel Kant Baltic Federal University, 236041 Kaliningrad, Russia; (M.S.); (O.T.)
| | - Michael Bader
- Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany; (S.M.); (M.P.); (M.B.); (N.A.)
| | - Natalia Alenina
- Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany; (S.M.); (M.P.); (M.B.); (N.A.)
- Institute of Translational Biomedicine, St. Petersburg State University, 199034 St. Petersburg, Russia
| | - Friederike Klempin
- School of Life Sciences, Immanuel Kant Baltic Federal University, 236041 Kaliningrad, Russia; (M.S.); (O.T.)
- Max Delbrück Center for Molecular Medicine, 13125 Berlin, Germany; (S.M.); (M.P.); (M.B.); (N.A.)
- Department of Psychiatry and Psychotherapy, Charité University Medicine, 10117 Berlin, Germany;
| |
Collapse
|
4
|
Matthes S, Merbach T, Fitschen J, Hoffmann M, Schlüter M. Influence of counterdiffusion effects on mass transfer coefficients in stirred tank reactors. Chemical Engineering Journal Advances 2021. [DOI: 10.1016/j.ceja.2021.100180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
5
|
Mordhorst A, Dhandapani P, Matthes S, Mosienko V, Rothe M, Todiras M, Self J, Schunck WH, Schütz A, Bader M, Alenina N. Phenylalanine hydroxylase contributes to serotonin synthesis in mice. FASEB J 2021; 35:e21648. [PMID: 33993565 DOI: 10.1096/fj.202100366r] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2021] [Revised: 04/11/2021] [Accepted: 04/21/2021] [Indexed: 12/31/2022]
Abstract
Serotonin is an important signaling molecule in the periphery and in the brain. The hydroxylation of tryptophan is the first and rate-limiting step of its synthesis. In most vertebrates, two enzymes have been described to catalyze this step, tryptophan hydroxylase (TPH) 1 and 2, with expression localized to peripheral and neuronal cells, respectively. However, animals lacking both TPH isoforms still exhibit about 10% of normal serotonin levels in the blood demanding an additional source of the monoamine. In this study, we provide evidence by the gain and loss of function approaches in in vitro and in vivo systems, including stable-isotope tracing in mice, that phenylalanine hydroxylase (PAH) is a third TPH in mammals. PAH contributes to serotonin levels in the blood, and may be important as a local source of serotonin in organs in which no other TPHs are expressed, such as liver and kidney.
Collapse
Affiliation(s)
- Alexander Mordhorst
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.,Charite - University Medicine, Berlin, Germany
| | - Priyavathi Dhandapani
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Susann Matthes
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Valentina Mosienko
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | | | - Mihail Todiras
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.,Nicolae Testemiţanu State University of Medicine and Pharmacy, Chișinău, Moldova
| | - Julie Self
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Wolf-Hagen Schunck
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Anja Schütz
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - Michael Bader
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.,Charite - University Medicine, Berlin, Germany.,Institute for Biology, University of Lübeck, Lübeck, Germany
| | - Natalia Alenina
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.,German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.,Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia.,Institute of Cytology, Russian Academy of Science, St. Petersburg, Russia
| |
Collapse
|
6
|
Peleg Y, Vincentelli R, Collins BM, Chen KE, Livingstone EK, Weeratunga S, Leneva N, Guo Q, Remans K, Perez K, Bjerga GEK, Larsen Ø, Vaněk O, Skořepa O, Jacquemin S, Poterszman A, Kjær S, Christodoulou E, Albeck S, Dym O, Ainbinder E, Unger T, Schuetz A, Matthes S, Bader M, de Marco A, Storici P, Semrau MS, Stolt-Bergner P, Aigner C, Suppmann S, Goldenzweig A, Fleishman SJ. Community-Wide Experimental Evaluation of the PROSS Stability-Design Method. J Mol Biol 2021; 433:166964. [PMID: 33781758 DOI: 10.1016/j.jmb.2021.166964] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 03/08/2021] [Accepted: 03/22/2021] [Indexed: 10/21/2022]
Abstract
Recent years have seen a dramatic improvement in protein-design methodology. Nevertheless, most methods demand expert intervention, limiting their widespread adoption. By contrast, the PROSS algorithm for improving protein stability and heterologous expression levels has been successfully applied to a range of challenging enzymes and binding proteins. Here, we benchmark the application of PROSS as a stand-alone tool for protein scientists with no or limited experience in modeling. Twelve laboratories from the Protein Production and Purification Partnership in Europe (P4EU) challenged the PROSS algorithm with 14 unrelated protein targets without support from the PROSS developers. For each target, up to six designs were evaluated for expression levels and in some cases, for thermal stability and activity. In nine targets, designs exhibited increased heterologous expression levels either in prokaryotic and/or eukaryotic expression systems under experimental conditions that were tailored for each target protein. Furthermore, we observed increased thermal stability in nine of ten tested targets. In two prime examples, the human Stem Cell Factor (hSCF) and human Cadherin-Like Domain (CLD12) from the RET receptor, the wild type proteins were not expressible as soluble proteins in E. coli, yet the PROSS designs exhibited high expression levels in E. coli and HEK293 cells, respectively, and improved thermal stability. We conclude that PROSS may improve stability and expressibility in diverse cases, and that improvement typically requires target-specific expression conditions. This study demonstrates the strengths of community-wide efforts to probe the generality of new methods and recommends areas for future research to advance practically useful algorithms for protein science.
Collapse
Affiliation(s)
- Yoav Peleg
- Department of Life Sciences Core Facilities (LSCF), Weizmann Institute of Science, Rehovot 7610001, Israel.
| | - Renaud Vincentelli
- Unité Mixte de Recherche (UMR) 7257, Centre National de la Recherche Scientifique (CNRS) Aix-Marseille Université, Architecture et Fonction des Macromolécules Biologiques (AFMB), Marseille, France
| | - Brett M Collins
- The University of Queensland, Institute for Molecular Bioscience, St. Lucia, Queensland 4072, Australia
| | - Kai-En Chen
- The University of Queensland, Institute for Molecular Bioscience, St. Lucia, Queensland 4072, Australia
| | - Emma K Livingstone
- The University of Queensland, Institute for Molecular Bioscience, St. Lucia, Queensland 4072, Australia
| | - Saroja Weeratunga
- The University of Queensland, Institute for Molecular Bioscience, St. Lucia, Queensland 4072, Australia
| | - Natalya Leneva
- The University of Queensland, Institute for Molecular Bioscience, St. Lucia, Queensland 4072, Australia
| | - Qian Guo
- The University of Queensland, Institute for Molecular Bioscience, St. Lucia, Queensland 4072, Australia
| | - Kim Remans
- European Molecular Biology Laboratory (EMBL), Protein Expression and Purification Core Facility, Meyerhofstrasse 1, 69117 Heidelberg, Germany
| | - Kathryn Perez
- European Molecular Biology Laboratory (EMBL), Protein Expression and Purification Core Facility, Meyerhofstrasse 1, 69117 Heidelberg, Germany
| | - Gro E K Bjerga
- NORCE Norwegian Research Centre, Postboks 22 Nygårdstangen, 5038 Bergen, Norway
| | - Øivind Larsen
- NORCE Norwegian Research Centre, Postboks 22 Nygårdstangen, 5038 Bergen, Norway
| | - Ondřej Vaněk
- Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030/8, 12840 Prague, Czech Republic
| | - Ondřej Skořepa
- Department of Biochemistry, Faculty of Science, Charles University, Hlavova 2030/8, 12840 Prague, Czech Republic
| | - Sophie Jacquemin
- Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique (CNRS), UMR 7104, Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, Université de Strasbourg, France
| | - Arnaud Poterszman
- Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique (CNRS), UMR 7104, Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, Université de Strasbourg, France
| | - Svend Kjær
- Structural Biology Science Technology Platform, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Evangelos Christodoulou
- Structural Biology Science Technology Platform, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Shira Albeck
- Department of Life Sciences Core Facilities (LSCF), Weizmann Institute of Science, Rehovot 7610001, Israel
| | - Orly Dym
- Department of Life Sciences Core Facilities (LSCF), Weizmann Institute of Science, Rehovot 7610001, Israel
| | - Elena Ainbinder
- Department of Life Sciences Core Facilities (LSCF), Weizmann Institute of Science, Rehovot 7610001, Israel
| | - Tamar Unger
- Department of Life Sciences Core Facilities (LSCF), Weizmann Institute of Science, Rehovot 7610001, Israel
| | - Anja Schuetz
- Max-Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Susann Matthes
- Max-Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Michael Bader
- Max-Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany; University of Lübeck, Institute for Biology, Ratzeburger Allee 160, 23562 Lübeck, Germany; Charité University Medicine, Charitéplatz 1, 10117 Berlin, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany
| | - Ario de Marco
- Laboratory for Environmental and Life Sciences, University of Nova Gorica, Slovenia
| | - Paola Storici
- Elettra Sincrotrone Trieste - SS 14 - km 163, 5 in Area Science Park, 34149 Basovizza, Trieste, Italy
| | - Marta S Semrau
- Elettra Sincrotrone Trieste - SS 14 - km 163, 5 in Area Science Park, 34149 Basovizza, Trieste, Italy
| | - Peggy Stolt-Bergner
- Vienna Biocenter Core Facilities GmbH, Dr. Bohr-gasse 3, 1030 Vienna, Austria
| | - Christian Aigner
- Vienna Biocenter Core Facilities GmbH, Dr. Bohr-gasse 3, 1030 Vienna, Austria
| | - Sabine Suppmann
- Max-Planck Institute of Biochemistry, Biochemistry Core Facility, Am Klopferspitz 18, 82152 Martinsried, Germany
| | - Adi Goldenzweig
- Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - Sarel J Fleishman
- Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.
| |
Collapse
|
7
|
Matthes S, Mosienko V, Popova E, Rivalan M, Bader M, Alenina N. Targeted Manipulation of Brain Serotonin: RNAi-Mediated Knockdown of Tryptophan Hydroxylase 2 in Rats. ACS Chem Neurosci 2019; 10:3207-3217. [PMID: 30977636 DOI: 10.1021/acschemneuro.8b00635] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in the biosynthesis of the biogenic monoamine serotonin (5-hydroxytryptamine, 5-HT). Two existing TPH isoforms are responsible for the generation of two distinct serotonergic systems in vertebrates. TPH1, predominantly expressed in the gastrointestinal tract and pineal gland, mediates 5-HT biosynthesis in non-neuronal tissues, while TPH2, mainly found in the raphe nuclei of the brain stem, is accountable for the production of 5-HT in the brain. Neuronal 5-HT is a key regulator of mood and behavior and its deficiency has been implicated in a variety of neuropsychiatric disorders, e.g., depression and anxiety. To gain further insights into the complexity of central 5-HT modulations of physiological and pathophysiological processes, a new transgenic rat model, allowing an inducible gene knockdown of Tph2, was established based on doxycycline-inducible shRNA-expression. Biochemical phenotyping revealed a functional knockdown of Tph2 mRNA expression following oral doxycycline administration, with subsequent reductions in the corresponding levels of TPH2 enzyme expression and activity. Transgenic rats showed also significantly decreased tissue levels of 5-HT and its degradation product 5-Hydroxyindoleacetic acid (5-HIAA) in the raphe nuclei, hippocampus, hypothalamus, and cortex, while peripheral 5-HT concentrations in the blood remained unchanged. In summary, this novel transgenic rat model allows inducible manipulation of 5-HT biosynthesis specifically in the brain and may help to elucidate the role of 5-HT in the pathophysiology of affective disorders.
Collapse
Affiliation(s)
- Susann Matthes
- Max-Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
- Institute for Biology, University of Lübeck, Ratzeburger Allee 160, 23562 Lübeck, Germany
| | - Valentina Mosienko
- Max-Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
- College of Medicine and Health, Institute of Biomedical and Clinical Sciences, University of Exeter, Hatherly Building, Prince of Wales Rd., EX4 4PS Exeter, United Kingdom
| | - Elena Popova
- Max-Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
| | - Marion Rivalan
- Charité University Medicine, Charitéplatz 1, 10117 Berlin, Germany
| | - Michael Bader
- Max-Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
- Institute for Biology, University of Lübeck, Ratzeburger Allee 160, 23562 Lübeck, Germany
- Charité University Medicine, Charitéplatz 1, 10117 Berlin, Germany
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, 13316 Berlin, Germany
- Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Straße 2, 10178 Berlin, Germany
| | - Natalia Alenina
- Max-Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany
- German Center for Cardiovascular Research (DZHK), Partner Site Berlin, 13316 Berlin, Germany
- Institute of Translational Biomedicine, St. Petersburg State University, Saint Petersburg 199034, Russia
| |
Collapse
|
8
|
Klempin F, Mosienko V, Matthes S, Villela DC, Todiras M, Penninger JM, Bader M, Santos RAS, Alenina N. Depletion of angiotensin-converting enzyme 2 reduces brain serotonin and impairs the running-induced neurogenic response. Cell Mol Life Sci 2018; 75:3625-3634. [PMID: 29679094 PMCID: PMC7079801 DOI: 10.1007/s00018-018-2815-y] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Revised: 04/05/2018] [Accepted: 04/11/2018] [Indexed: 12/20/2022]
Abstract
Physical exercise induces cell proliferation in the adult hippocampus in rodents. Serotonin (5-HT) and angiotensin (Ang) II are important mediators of the pro-mitotic effect of physical activity. Here, we examine precursor cells in the adult brain of mice lacking angiotensin-converting enzyme (ACE) 2, and explore the effect of an acute running stimulus on neurogenesis. ACE2 metabolizes Ang II to Ang-(1–7) and is essential for the intestinal uptake of tryptophan (Trp), the 5-HT precursor. In ACE2-deficient mice, we observed a decrease in brain 5-HT levels and no increase in the number of BrdU-positive cells following exercise. Targeting the Ang II/AT1 axis by blocking the receptor, or experimentally increasing Trp/5-HT levels in the brain of ACE2-deficient mice, did not rescue the running-induced effect. Furthermore, mice lacking the Ang-(1–7) receptor, Mas, presented a normal neurogenic response to exercise. Our results identify ACE2 as a novel factor required for exercise-dependent modulation of adult neurogenesis and essential for 5-HT metabolism.
Collapse
Affiliation(s)
- Friederike Klempin
- Max-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany. .,Charité, University Medicine Berlin, Berlin, Germany.
| | - Valentina Mosienko
- Max-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.,University of Exeter Medical School, Hatherly Building D11, Exeter, EX4 4PS, UK
| | - Susann Matthes
- Max-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany
| | - Daniel C Villela
- Federal University of Minas Gerais (UFmG), ICB, Belo Horizonte, MG, 6627, Brazil.,Federal University of Jequitinhonha and Mucuri Valleys, Diamantina, MG, Brazil
| | - Mihail Todiras
- Max-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany
| | - Josef M Penninger
- Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria
| | - Michael Bader
- Max-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.,Charité, University Medicine Berlin, Berlin, Germany.,Institute of Biology, University of Lübeck, 23562, Lübeck, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany
| | - Robson A S Santos
- Federal University of Minas Gerais (UFmG), ICB, Belo Horizonte, MG, 6627, Brazil
| | - Natalia Alenina
- Max-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.,DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.,Institute of Translational Biomedicine, St. Petersburg State University, Saint Petersburg, 199034, Russia
| |
Collapse
|
9
|
Matthes S, Bader M. Peripheral Serotonin Synthesis as a New Drug Target. Trends Pharmacol Sci 2018; 39:560-572. [PMID: 29628275 DOI: 10.1016/j.tips.2018.03.004] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2018] [Revised: 03/13/2018] [Accepted: 03/14/2018] [Indexed: 12/19/2022]
Abstract
The first step in serotonin (5-HT) biosynthesis is catalyzed by tryptophan hydroxylase (TPH). There are two independent sources of the monoamine that have distinct functions: first, the TPH1-expressing enterochromaffin cells (ECs) of the gut; second, TPH2-expressing serotonergic neurons. TPH1-deficient mice revealed that peripheral 5-HT plays important roles in platelet function and in inflammatory and fibrotic diseases of gut, pancreas, lung, and liver. Therefore, TPH inhibitors were developed which cannot pass the blood-brain barrier to specifically block peripheral 5-HT synthesis. They showed therapeutic efficacy in several rodent disease models, and telotristat ethyl is the first TPH inhibitor to be approved for the treatment of carcinoid syndrome. We review this development and discuss further therapeutic options for these compounds.
Collapse
Affiliation(s)
- Susann Matthes
- Max-Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany; University of Lübeck, Institute for Biology, Ratzeburger Allee 160, 23562 Lübeck, Germany
| | - Michael Bader
- Max-Delbrück Center for Molecular Medicine (MDC), Robert-Rössle-Straße 10, 13125 Berlin-Buch, Germany; University of Lübeck, Institute for Biology, Ratzeburger Allee 160, 23562 Lübeck, Germany; Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Straße 2, 10178 Berlin, Germany; Charité University Medicine, Charitéplatz 1, 10117 Berlin, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.
| |
Collapse
|
10
|
Götschke J, Mertsch P, Bischof M, Kneidinger N, Matthes S, Renner E, Schultz K, Traidl-Hoffmann C, Duchna HW, Behr J, Schmude J, Huber RM, Milger K. Perception of climate change in patients with chronic lung disease. Pneumologie 2018. [DOI: 10.1055/s-0037-1619415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- J Götschke
- Medizinische Klinik V, Klinikum der Universität München
| | - P Mertsch
- Medizinische Klinik V, Klinikum der Universität München
| | - M Bischof
- Wirtschaftsgeografie und Tourismusforschung, Universität München
| | - N Kneidinger
- Medizinische Klinik V, Klinikum der Universität München
| | - S Matthes
- Medizinische Klinik V, Klinikum der Universität München
| | - E Renner
- Christine Kühne – Center for Allergy Research and Education, CK-Care, Davos
| | | | - C Traidl-Hoffmann
- Chair and Institute of Environmental Medicine, Unika-T, Technical University Munich and Helmholtz Zentrum München; German Research Center for Environmental Health, Augsburg
| | | | - J Behr
- Medizinische Klinik V, Klinikum der Universität München
| | - J Schmude
- Wirtschaftsgeografie und Tourismusforschung, Universität München
| | - RM Huber
- Medizinische Klinik V, Klinikum der Universität München
| | - K Milger
- Medizinische Klinik V, Klinikum der Universität München
| |
Collapse
|
11
|
Stelzer D, Weber A, Ihle F, Matthes S, Ceelen F, Zimmermann G, Kneidinger N, Schramm R, Winter H, Zoller M, Vogeser M, Behr J, Neurohr C. Posaconazole liquid vs tablet formulation in lung transplant recipients. Mycoses 2017; 61:186-194. [DOI: 10.1111/myc.12724] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2017] [Revised: 08/13/2017] [Accepted: 10/29/2017] [Indexed: 12/12/2022]
Affiliation(s)
- D. Stelzer
- Department of Internal Medicine V; LMU-Munich; Munich Germany
- Comprehensive Pneumology Center; Member of the German Center for Lung Research DZL; Munich Germany
- Hospital Pharmacy; LMU-Munich; Munich Germany
| | - A. Weber
- Hospital Pharmacy; LMU-Munich; Munich Germany
| | - F. Ihle
- Department of Internal Medicine V; LMU-Munich; Munich Germany
- Comprehensive Pneumology Center; Member of the German Center for Lung Research DZL; Munich Germany
| | - S. Matthes
- Department of Internal Medicine V; LMU-Munich; Munich Germany
- Comprehensive Pneumology Center; Member of the German Center for Lung Research DZL; Munich Germany
| | - F. Ceelen
- Department of Internal Medicine V; LMU-Munich; Munich Germany
- Comprehensive Pneumology Center; Member of the German Center for Lung Research DZL; Munich Germany
| | - G. Zimmermann
- Department of Internal Medicine V; LMU-Munich; Munich Germany
- Comprehensive Pneumology Center; Member of the German Center for Lung Research DZL; Munich Germany
| | - N. Kneidinger
- Department of Internal Medicine V; LMU-Munich; Munich Germany
- Comprehensive Pneumology Center; Member of the German Center for Lung Research DZL; Munich Germany
| | - R. Schramm
- Department of Cardiac Surgery; LMU-Munich; Munich Germany
| | - H. Winter
- Department of Thoracic Surgery; LMU-Munich; Munich Germany
| | - M. Zoller
- Department of Anesthesiology; LMU-Munich; Munich Germany
| | - M. Vogeser
- Institute of Laboratory Medicine; LMU-Munich; Munich Germany
| | - J. Behr
- Department of Internal Medicine V; LMU-Munich; Munich Germany
- Comprehensive Pneumology Center; Member of the German Center for Lung Research DZL; Munich Germany
| | - C. Neurohr
- Department of Internal Medicine V; LMU-Munich; Munich Germany
- Comprehensive Pneumology Center; Member of the German Center for Lung Research DZL; Munich Germany
| |
Collapse
|
12
|
Munker D, Arnold P, Ceelen F, Kneidinger N, Leuschner G, Prechtl C, Matthes S, Veit T, Behr J, Neurohr C. Kortisonstoßtherapie bei Verschlechterung der Lungenfunktion nach Lungentransplantation und Ausschluss einer akuten zellulären Abstoßungsreaktion. Pneumologie 2017. [DOI: 10.1055/s-0037-1598292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- D Munker
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - P Arnold
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - F Ceelen
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - N Kneidinger
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - G Leuschner
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - C Prechtl
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - S Matthes
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - T Veit
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - J Behr
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - C Neurohr
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| |
Collapse
|
13
|
Leuschner G, Stocker F, Veit T, Kneidinger N, Ceelen F, Arnold P, Munker D, Matthes S, Behr J, Neurohr C. Lungentransplantation bei Patienten mit bestehender Pirfenidontherapie: eine Fallstudie. Pneumologie 2017. [DOI: 10.1055/s-0037-1598291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- G Leuschner
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - F Stocker
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - T Veit
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - N Kneidinger
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - F Ceelen
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - P Arnold
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - D Munker
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - S Matthes
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - J Behr
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - C Neurohr
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| |
Collapse
|
14
|
Ceelen F, Burger C, Kneidinger N, Matthes S, Leuschner G, Arnold P, Munker D, Veit T, Dinkel J, Behr J, Neurohr C. Stellenwert der Surveillance-Computertomografie nach Lungentransplantation. Pneumologie 2017. [DOI: 10.1055/s-0037-1598562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- F Ceelen
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - C Burger
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - N Kneidinger
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - S Matthes
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - G Leuschner
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - P Arnold
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - D Munker
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - T Veit
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - J Dinkel
- Institut für Klinische Radiologie, Klinikum der Universität München
| | - J Behr
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - C Neurohr
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| |
Collapse
|
15
|
Matthes S, Barton J, Stadler J, Kneidinger N, Ceelen F, Leuschner G, Arnold P, Munker D, Veit T, Villena-Hermoza H, Frankenberger M, Behr J, Neurohr C. Phänotypische Charakterisierung von Patienten mit schwerer chronisch obstruktiver Lungenerkrankung (COPD). Pneumologie 2017. [DOI: 10.1055/s-0037-1598546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- S Matthes
- Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität München, Comprehensive Pneumology Center Munich (Cpc-M), Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - J Barton
- Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität München, Comprehensive Pneumology Center Munich (Cpc-M), Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - J Stadler
- Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität München, Comprehensive Pneumology Center Munich (Cpc-M), Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - N Kneidinger
- Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität München, Comprehensive Pneumology Center Munich (Cpc-M), Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - F Ceelen
- Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität München, Comprehensive Pneumology Center Munich (Cpc-M), Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - G Leuschner
- Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität München, Comprehensive Pneumology Center Munich (Cpc-M), Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - P Arnold
- Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität München, Comprehensive Pneumology Center Munich (Cpc-M), Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - D Munker
- Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität München, Comprehensive Pneumology Center Munich (Cpc-M), Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - T Veit
- Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität München, Comprehensive Pneumology Center Munich (Cpc-M), Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - H Villena-Hermoza
- Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität München, Comprehensive Pneumology Center Munich (Cpc-M), Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - M Frankenberger
- Cpc Comprehensive Pneumology Center, Forschungsambulanz Helmholtz Zentrum München; Ludwig-Maximilians Universität und Asklepios Klinik Gauting
| | - J Behr
- Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität München, Comprehensive Pneumology Center Munich (Cpc-M), Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - C Neurohr
- Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität München, Comprehensive Pneumology Center Munich (Cpc-M), Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| |
Collapse
|
16
|
Arnold P, Munker D, Kneidinger N, Ceelen F, Leuschner G, Matthes S, Veit T, Prechtl C, Behr J, Neurohr C. Volumenbelastung bei Patienten mit fortgeschrittener Lungenerkrankung. Pneumologie 2017. [DOI: 10.1055/s-0037-1598569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- P Arnold
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - D Munker
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - N Kneidinger
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - F Ceelen
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - G Leuschner
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - S Matthes
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - T Veit
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - C Prechtl
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - J Behr
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| | - C Neurohr
- Medizinische Klinik und Poliklinik V, Klinikum der Universität München, Mitglied des Deutschen Zentrums für Lungenforschung (Dzl)
| |
Collapse
|
17
|
Mosienko V, Beis D, Pasqualetti M, Waider J, Matthes S, Qadri F, Bader M, Alenina N. Life without brain serotonin: reevaluation of serotonin function with mice deficient in brain serotonin synthesis. Behav Brain Res 2014; 277:78-88. [PMID: 24928769 DOI: 10.1016/j.bbr.2014.06.005] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2014] [Revised: 05/23/2014] [Accepted: 06/02/2014] [Indexed: 12/19/2022]
Abstract
Tryptophan hydroxylase (TPH) is a rate limiting enzyme in the synthesis of serotonin (5-HT), a monoamine which works as an autacoid in the periphery and as a neurotransmitter in the central nervous system. In 2003 we have discovered the existence of a second Tph gene, which is expressed exclusively in the brain, and, therefore, is responsible for the 5-HT synthesis in the central nervous system. In the following years several research groups have independently generated Tph2-deficient mice. In this review we will summarize the data gained from the existing mouse models with constitutive or conditional deletion of the Tph2 gene, focusing on biochemical, developmental, and behavioral consequences of Tph2-deficiency.
Collapse
Affiliation(s)
| | - Daniel Beis
- Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany
| | - Massimo Pasqualetti
- Department of Biology, Unit of Cell and Developmental Biology, University of Pisa, Pisa, Italy
| | - Jonas Waider
- Laboratory of Translational Neuroscience, Division of Molecular Psychiatry, Department of Psychiatry, Psychosomatics, and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
| | - Susann Matthes
- Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany
| | | | - Michael Bader
- Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany
| | - Natalia Alenina
- Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany.
| |
Collapse
|
18
|
Mosienko V, Matthes S, Hirth N, Beis D, Flinders M, Bader M, Hansson AC, Alenina N. Adaptive changes in serotonin metabolism preserve normal behavior in mice with reduced TPH2 activity. Neuropharmacology 2014; 85:73-80. [PMID: 24863038 DOI: 10.1016/j.neuropharm.2014.05.015] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2014] [Revised: 05/02/2014] [Accepted: 05/10/2014] [Indexed: 01/29/2023]
Abstract
Polymorphisms in the TPH2 gene coding for the serotonin synthesizing enzyme in the brain are considered as risk factors associated with depression and anxiety in humans. However, whether a certain variation in the TPH2 gene leads to decreased brain serotonin production and development of psychological abnormalities remains unresolved. We generated a new mouse model, carrying one Tph2-null allele and one Tph21473G-allele, coding for a hypoactive form of the enzyme. We tested these mice along with C57BL/6 mice (Tph2C/C), congenic C57BL/6 mice homozygous for the Tph21473G-allele (Tph2G/G), and heterozygous Tph2-deficient mice (Tph2C/-) for anxiety- and depression-like behavior, and evaluated brain serotonin metabolism and 5-HT1AR signaling by high-performance liquid chromatography and quantitative autoradiography, respectively. Progressive reduction in TPH2 activity had no effect on emotional behavior, and only slightly affected brain serotonin levels. However, serotonin degradation rate was drastically decreased in mice with reduced TPH2 activity, thereby compensating for the lowered rate of serotonin production in these mice. In addition, the hypothermic response to the 5-HT1AR agonist, 8-OH-DPAT, was attenuated in mice with reduced serotonin production. In contrast, 5-HT1A autoreceptor density and G-protein coupling were not changed in mice with gradual decrease in central serotonin. Taken together, these data suggest that in conditions of reduced serotonin production lowered serotonin degradation rate contributes to the maintenance of brain serotonin at levels sufficient for adequate behavior responses. These findings reveal that decreased TPH2 activity cannot be considered a reliable predisposition factor for impaired emotional behavior.
Collapse
Affiliation(s)
| | - Susann Matthes
- Max-Delbrueck-Center for Molecular Medicine, Berlin-Buch, Germany; Humboldt-Universität Berlin, Berlin, Germany
| | - Natalie Hirth
- Institute of Psychopharmacology at the Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Daniel Beis
- Max-Delbrueck-Center for Molecular Medicine, Berlin-Buch, Germany; Humboldt-Universität Berlin, Berlin, Germany
| | - Michael Flinders
- Max-Delbrueck-Center for Molecular Medicine, Berlin-Buch, Germany
| | - Michael Bader
- Max-Delbrueck-Center for Molecular Medicine, Berlin-Buch, Germany
| | - Anita C Hansson
- Institute of Psychopharmacology at the Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Natalia Alenina
- Max-Delbrueck-Center for Molecular Medicine, Berlin-Buch, Germany.
| |
Collapse
|
19
|
Lee GS, Simpson C, Sun BH, Yao C, Foer D, Sullivan B, Matthes S, Alenina N, Belsky J, Bader M, Insogna KL. Measurement of plasma, serum, and platelet serotonin in individuals with high bone mass and mutations in LRP5. J Bone Miner Res 2014; 29:976-81. [PMID: 24038240 PMCID: PMC3935983 DOI: 10.1002/jbmr.2086] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2013] [Revised: 08/12/2013] [Accepted: 08/17/2013] [Indexed: 11/08/2022]
Abstract
It has recently been suggested that the low-density lipoprotein receptor-related protein 5 (LRP5) regulates bone mass by suppressing secretion of serotonin from duodenal enterochromaffin cells. In mice with targeted expression of a high bone mass-causing (HBM-causing) LRP5 mutation and in humans with HBM LRP5 mutations, circulating serotonin levels have been reported to be lower than in controls whereas individuals with loss-of-function mutations in LRP5 have high blood serotonin. In contrast, others have reported that conditionally activating a knock-in allele of an HBM-causing LRP5 mutation in several tissues, or genetic deletion of LRP5 in mice has no effect on serum serotonin levels. To further explore the possible association between HBM-causing LRP5 mutations and circulating serotonin, levels of the hormone were measured in the platelet poor plasma (PPP), serum, and platelet pellet (PP) of 16 affected individuals from 2 kindreds with HBM-causing LRP5 mutations (G171V and N198S) and 16 age-matched controls. When analyzed by HPLC, there were no differences in levels of serotonin in PPP and PP between affected individuals and age-matched controls. Similarly, when analyzed by ELISA, there were no differences in PPP or PP between these two groups. By ELISA, serum levels of serotonin were higher in the affected individuals when compared to age-matched controls. A subgroup analysis of only the G171V subjects (n=14) demonstrated that there were no differences in PPP and PP serotonin between affected individuals and controls when analyzed by HPLC. PP serotonin was lower in the affected individuals when measured by ELISA but serum serotonin levels were not different. We conclude that there is no change in PPP serotonin in individuals with HBM-causing mutations in LRP5.
Collapse
Affiliation(s)
- Grace S Lee
- Yale University School of Medicine, New Haven, CT, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Priegnitz C, Treml M, Matthes S, Richter K, Randerath WJ. Prävalenz eines Overlapsyndroms bei unselektionierten stationären COPD-Patienten. Pneumologie 2014. [DOI: 10.1055/s-0034-1367963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Matthes S, Böing S, Priegnitz C, Anduleit N, Randerath WJ. COPD, Adipositas und nicht invasive Beatmung. Pneumologie 2014. [DOI: 10.1055/s-0034-1367741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
Priegnitz C, Matthes S, Treml M, Anduleit N, Randerath WJ. COPD – Einfluss von begleitender pulmonaler Hypertonie auf die Lebensqualität. Pneumologie 2014. [DOI: 10.1055/s-0034-1367738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Priegnitz C, Treml M, Richter K, Matthes S, Randerath WJ. Pulmonale Hypertonie bei chronisch obstruktiver Lungenerkrankung: vorläufige Daten einer Langzeitverlaufsbeobachtung. Pneumologie 2014. [DOI: 10.1055/s-0034-1367825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
24
|
Bode S, Bose RK, Matthes S, Ehrhardt M, Seifert A, Schacher FH, Paulus RM, Stumpf S, Sandmann B, Vitz J, Winter A, Hoeppener S, Garcia SJ, Spange S, van der Zwaag S, Hager MD, Schubert US. Self-healing metallopolymers based on cadmium bis(terpyridine) complex containing polymer networks. Polym Chem 2013. [DOI: 10.1039/c3py00288h] [Citation(s) in RCA: 113] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
25
|
Abstract
Serotonin is a major neurotransmitter in the central nervous system (CNS). Dysregulation of serotonin transmission in the CNS is reported to be related to different psychiatric disorders in humans including depression, impulsive aggression and anxiety disorders. The most frequently prescribed antidepressants and anxiolytics target the serotonergic system. However, these drugs are not effective in 20-30% of cases. The causes of this failure as well as the molecular mechanisms involved in the origin of psychological disorders are poorly understood. Biosynthesis of serotonin in the CNS is initiated by tryptophan hydroxylase 2 (TPH2). In this study, we used Tph2-deficient (Tph2(-/-)) mice to evaluate the impact of serotonin depletion in the brain on mouse behavior. Tph2(-/-) mice exhibited increased depression-like behavior in the forced swim test but not in the tail suspension test. In addition, they showed decreased anxiety-like behavior in three different paradigms: elevated plus maze, marble burying and novelty-suppressed feeding tests. These phenotypes were accompanied by strong aggressiveness observed in the resident-intruder paradigm. Despite carrying only one copy of the gene, heterozygous Tph2(+/-) mice showed only 10% reduction in brain serotonin, which was not sufficient to modulate behavior in the tested paradigms. Our findings provide unequivocal evidence on the pivotal role of central serotonin in anxiety and aggression.
Collapse
Affiliation(s)
- V Mosienko
- Department of Molecular Biology of Peptide Hormones, Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany,Faculty of Mathematics and Natural Sciences, Department of Biology, Humboldt-Universität Berlin, Berlin, Germany
| | - B Bert
- Institute of Pharmacology and Toxicology, School of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany
| | - D Beis
- Department of Molecular Biology of Peptide Hormones, Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany,Faculty of Mathematics and Natural Sciences, Department of Biology, Humboldt-Universität Berlin, Berlin, Germany
| | - S Matthes
- Department of Molecular Biology of Peptide Hormones, Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany,Faculty of Mathematics and Natural Sciences, Department of Biology, Humboldt-Universität Berlin, Berlin, Germany
| | - H Fink
- Institute of Pharmacology and Toxicology, School of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany
| | - M Bader
- Department of Molecular Biology of Peptide Hormones, Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany
| | - N Alenina
- Department of Molecular Biology of Peptide Hormones, Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany,Department of Molecular Biology of Peptide Hormones, Max-Delbrueck-Center for Molecular Medicine, Robert-Roessle Street 10, 13125 Berlin, Germany. E-mail:
| |
Collapse
|
26
|
Styczynski J, Gil L, Ljungman P, Donnelly J, Martino R, Theunissen K, Maertens J, Kalwak K, Hubacek P, Sica S, van der Velden W, Omar H, Nozzoli C, Fagioli F, Matthes S, Diaz M, Migliavacca M, Balduzzi A, Faraci M, Tomaszewska A, de la Camara R, Hoek J, Einsele H, Cesaro S. Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder in Children Treated with Rituximab: The Impact of Viral Load and Non-Lymphoid Tissue Involvement. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
27
|
Fritsch G, Witt V, Matthes S, Dworzak M, Artwohl M, Clarke D, Mathew A. Improved Post-Thaw Stability Validation of Peripheral Blood Cell Products Utilizing the Intracellular-Like Cryostor Cryopreservation Solution, and Preliminary Results of Clinical Application. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.178] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
28
|
Frömmel S, Köhler M, Matthes S, Werner A, Böhmer U, Bley T. Biomassebestimmung von Weißfäulepilzen in Festphasenkultur mittels RNA- und DNA-Bestimmung. CHEM-ING-TECH 2010. [DOI: 10.1002/cite.201050170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
29
|
Fritsch G, Witt V, Dubovsky J, Matthes S, Peters C, Buchinger P, Printz D, Handgretinger R, Lion T, Gadner H. Flow cytometric monitoring of hematopoietic reconstitution in myeloablated patients following allogeneic transplantation. Cytotherapy 2010; 1:295-309. [PMID: 20426555 DOI: 10.1080/0032472031000141265] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
BACKGROUND We report a routine flow cytometric (FACS) approach to quantify circulating leukocytes (NC) in myeloablated patients before and during regeneration after allogeneic transplantation of either whole bone marrow (BM) or of highly purified (> 99%) blood-derived CD34(+) cells (PBSC). METHODS Blood samples were analyzed daily between infusion of the transplant and hematopoietic reconstitution. Significant differences in the composition of NC types and CD34(+) cells were observed between the two CD34 sources. The detection threshold for NC was roughly 1 cell per w L blood. RESULTS The cell nadir of < 100 NC/ microL was reached on Day +4 (BM) and on day 0 (PBSC), when unusual CD34(+) cells of recipient genotype were detected in all patients. They were not clonogenic, showed high CD34 expression, but were negative for CD45, CD38, CD33, CD50, HLA-DR and Stro-1. Between Days +5 and +16, the onset of hematopoietic reconstitution was clearly detectable in multi-parameter evaluation of the FACS data. This was a median of 3.5 days before NC increased above 200/ w L blood and 4-10 days before granulocyte counts were > 500/ microL. It was marked by the appearance of monocytes, immature (CD38(+)) granulocytes, and clonogenic donor CD34(+) cells exhibited normal size and phenotype. DISCUSSION We conclude that dynamic FACS analyses can reliably detect hematopoietic reconstitution, but also graft rejection, before a visible increase NC numbers. This may have considerable impact on clinical management strategies.
Collapse
Affiliation(s)
- G Fritsch
- Children's Cancer Research Institute, St. Anna Kinderspital, Vienna, Austria
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
|
31
|
|
32
|
Matthes S, Mosienko V, Bashammakh S, Alenina N, Bader M. Tryptophan Hydroxylase as Novel Target for the Treatment of Depressive Disorders. Pharmacology 2010; 85:95-109. [DOI: 10.1159/000279322] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2009] [Accepted: 11/17/2009] [Indexed: 11/19/2022]
|
33
|
Eyring V, Waugh DW, Bodeker GE, Cordero E, Akiyoshi H, Austin J, Beagley SR, Boville BA, Braesicke P, Brühl C, Butchart N, Chipperfield MP, Dameris M, Deckert R, Deushi M, Frith SM, Garcia RR, Gettelman A, Giorgetta MA, Kinnison DE, Mancini E, Manzini E, Marsh DR, Matthes S, Nagashima T, Newman PA, Nielsen JE, Pawson S, Pitari G, Plummer DA, Rozanov E, Schraner M, Scinocca JF, Semeniuk K, Shepherd TG, Shibata K, Steil B, Stolarski RS, Tian W, Yoshiki M. Multimodel projections of stratospheric ozone in the 21st century. ACTA ACUST UNITED AC 2007. [DOI: 10.1029/2006jd008332] [Citation(s) in RCA: 283] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
34
|
Dänicke S, Valenta H, Matthes S. On the interactions between Fusarium toxin-contaminated wheat and nonstarch polysaccharide hydrolyzing enzymes in diets of broilers on performance, intestinal viscosity, and carryover of deoxynivalenol. Poult Sci 2007; 86:291-8. [PMID: 17234842 DOI: 10.1093/ps/86.2.291] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Wheat was inoculated with Fusarium culmorum. Broiler diets were formulated to contain this Fusarium-infected wheat (FIW) or control wheat (CW) at a proportion of 60% and were prepared without and with an exogenous nonstarch polysaccharide (NSP) hydrolyzing enzyme preparation [endo-1,4-beta-xylanase (EC 3.2.1.8) 1,000 FXU/g; ZY68, Lohmann Animal Health GmbH & Co. KG, Cuxhaven, Germany] to test the hypothesis that Fusarium infection-related increases in NSP hydrolyzing enzyme activities could compensate for the deleterious effects of the fungal-origin mycotoxins such as deoxynivalenol (DON). Deoxynivalenol concentration of CW and FIW amounted to 0.045 and 2.5 mg/kg of DM, respectively. After 35 d, the level of feed intake was generally lower in broilers fed the diets containing the FIW. Feed intake was stimulated by the addition of the NSP enzyme to both diet types. Similar relationships were observed for live weight gain, although the enzyme effect was much more pronounced for the CW-fed broilers, who performed even worse than the broilers fed the unsupplemented FIW. Viscosity was significantly reduced in the jejunum and the ileum by supplemental exogenous NSP hydrolyzing enzyme. However, this effect was more pronounced when the enzyme was added to the control diet, as indicated by the significant interactions between wheat and NSP enzyme. Concentrations of DON and its metabolite deepoxy-DON in plasma, bile, liver, and breast meat were lower than the detection limits of the applied HPLC-method. Overall, it can be concluded that feeding FIW might positively influence broiler performance and nutritional physiology, as indicated by the reduced intestinal viscosity and the less pronounced effects of addition of an exogenous NSP hydrolyzing enzyme preparation.
Collapse
Affiliation(s)
- S Dänicke
- Institute of Animal Nutrition, Federal Agricultural Research Centre, Braunschweig (FAL), Bundesallee 50, D-38116 Braunschweig, Germany.
| | | | | |
Collapse
|
35
|
Dänicke S, Valenta H, Ueberschär KH, Matthes S. On the interactions betweenFusariumtoxin-contaminated wheat and non-starch-polysaccharide hydrolysing enzymes in turkey diets on performance, health and carry-over of deoxynivalenol and zearalenone. Br Poult Sci 2007; 48:39-48. [PMID: 17364539 DOI: 10.1080/00071660601148161] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
1. Diets with increasing proportions of Fusarium toxin-contaminated wheat (0, 170, 340 and 510 g CW/kg) were fed to male turkeys (BUT Big 6) from d 21 to d 56 of age. Each diet was tested with or without a non-starch-polysaccharide (NSP) hydrolysing enzyme preparation. Dietary deoxynivalenol (DON) and zearalenone (ZON) concentrations were successively increased up to approximately 5.4 and 0.04 mg/kg, respectively. 2. Weight gain decreased slightly with increasing proportions of CW, by 1.6, 0.7 and 3.6%, whereas other performance parameters remained unaffected. NSP enzyme supplements to the diets had no influence. 3. The weight of the emptied jejunum plus ileum, relative to live weight, decreased in a dose-related fashion whereby the NSP enzyme exerted an additional weight-decreasing effect. A similar weight-decreasing NSP enzyme effect was noted for heart weights. Activity of glutamate dehydrogenase in serum was significantly increased in groups fed the diets with the highest CW proportion, whereas gamma-glutamyl-transferase remained unaltered. 4. Viscosity in the small intestine was significantly reduced by supplementing the diets with the NSP enzyme. This effect successively decreased with increasing proportions of the CW. 5. Concentrations of DON and of its de-epoxidised metabolite de-epoxy-DON in plasma, liver and breast meat were lower than the detection limits of 2 ng/ml (plasma) and 4 ng/g, respectively, of the applied HPLC method. DON concentration in bile reached up to 13 to 23 ng/ml whereas de-epoxy-DON concentration was lower than 4 ng/ml. 6. ZON or its metabolites were not detectable in plasma, liver or breast meat (detection limits of the HPLC method were 1, 0.5 and 5 ng/g for ZON, alpha-zearalenol (ZOL) and beta-ZOL, respectively). Concentrations of ZON and alpha-ZOL in bile increased with dietary ZON concentration. The mean proportions of ZON, alpha-ZOL and beta-ZOL of the sum of all three metabolites were 19, 77 and 4%, respectively.
Collapse
Affiliation(s)
- S Dänicke
- Institute of Animal Nutrition, Federal Agricultural Research Centre, Braunschweig (FAL), Braunschweig, Celle, Germany.
| | | | | | | |
Collapse
|
36
|
Ueberschär KH, Matthes S. Dose–response feeding study of chlorinated paraffins in broiler chickens: effects on growth rate and tissue distribution. ACTA ACUST UNITED AC 2004; 21:943-8. [PMID: 15712519 DOI: 10.1080/02652030400006833] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Even with the highest additions of 100mg kg(-1) short-chain (C10-C13) chlorinated paraffins (CP) to feed, the health of broilers was not adversely affected during a 31-day feeding experiment. In addition, 1 and 3 weeks after the experiment started, growth rate and feed consumption of the young animals were not impaired. No significant influence on mortality, organ weight relative to live weight or performance (weight gain, feed consumption) was noted. The CP concentrations in abdominal fat, meat, liver and kidneys were related linearly to the CP concentration of the feed. The highest contents were analysed in fat and the faeces, and the lowest concentrations were found in blood, meat and bile fluid. Less than 5% of the CP amount consumed was incorporated into the body, without taking the head, gut, feet and feathers into account.
Collapse
Affiliation(s)
- K H Ueberschär
- Institute of Animal Nutrition, Federal Agricultural Research Centre, Braunschweig (FAL), D-29223 Celle, Germany.
| | | |
Collapse
|
37
|
Dänicke S, Ueberschär KH, Valenta H, Matthes S, Matthäus K, Halle I. Effects of graded levels ofFusarium-toxin-contaminated wheat in Pekin duck diets on performance, health and metabolism of deoxynivalenol and zearalenone. Br Poult Sci 2004; 45:264-72. [PMID: 15222424 DOI: 10.1080/00071660410001715876] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
1. Diets with increasing proportions of Fusarium-toxin-contaminated wheat were fed to Pekin ducks for 49 d in order to titrate the lowest effect level. Dietary deoxynivalenol (DON) and zearalenone (ZON) concentrations were successively increased up to 6 to 7 mg/kg and 0.05 to 0.06 mg/kg, respectively. 2. Feed intake, live weight gain and feed to gain ratio were not influenced by dietary treatment. 3. Gross macroscopic inspection of the upper digestive tract did not reveal any signs of irritation, inflammation or other pathological changes. The weight of the bursa of Fabricius, relative to live weight, decreased in a dose-related fashion. Activities of glutamate dehydrogenase and gamma-glutamyl-transferase in serum were either unaffected or inconsistently affected by dietary treatments. 4. Concentrations of DON and of its de-epoxydised metabolite in plasma and bile were lower than the detection limits of 6 and 16 ng/ml, respectively, of the applied high performance liquid chromatography (HPLC) method. 5. ZON or its metabolites were not detectable in plasma and livers (detection limits of the HPLC method were 1, 0.5 and 5 ng/g for ZON, alpha-zearalenol (alpha-ZOL) and beta-zearalenol (beta-ZOL), respectively). Concentrations of ZON, alpha-ZOL and beta-ZOL in bile increased linearly with dietary ZON concentration. The mean proportions of ZON, alpha-ZOL and beta-ZOL of the sum of all three metabolites were 80, 16 and 4%, respectively. 6. Taken together, it can be concluded that dietary DON and ZON concentrations up to 6 and 0.06 mg/kg, respectively, did not adversely affect performance and health of growing Pekin ducks.
Collapse
Affiliation(s)
- S Dänicke
- Institute of Animal Nutrition, Federal Agricultural Research Centre, Braunschweig (FAL), Braunschweig, Germany.
| | | | | | | | | | | |
Collapse
|
38
|
Dänicke S, Matthes S, Halle I, Ueberschär KH, Döll S, Valenta H. Effects of graded levels of Fusarium toxin-contaminated wheat and of a detoxifying agent in broiler diets on performance, nutrient digestibility and blood chemical parameters. Br Poult Sci 2003; 44:113-26. [PMID: 12737233 DOI: 10.1080/0007166031000085300] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
1. A growth experiment was carried out with male broilers from d 1 to d 35 of age in order to evaluate the effects of the addition of a detoxifying agent (Mycofix Plus, Biomin GmbH, Herzogenburg, Austria) at different dietary proportions of wheat (0, 16.5, 33, 49.5 and 66%) contaminated with Fusarium mycotoxins (21.2 mg of deoxynivalenol and 406 microg of zearalenone, ZON, per kg of wheat) on growth performance, nutrient and zearalenone balance and clinical-chemical parameters. 2. An increase in dietary mycotoxin concentration resulted in a linearly related decrease in feed intake, a slight decrease in weight gain and an improvement in feed to gain ratio. 3. Apparent protein digestibility and net protein utilisation were higher in diets containing exclusively Fusarium toxin-contaminated wheat than control diets. 4. The proportions of beta-zearalenol, alpha-zearalenol and ZON of total ZON metabolites in excreta of broilers fed on the diets containing the Fusarium toxin-contaminated wheat were approximately 3, 21 and 76%. 5. Serum antibody titres to Newcastle disease virus decreased in a linear fashion with increasing mycotoxin concentration in the diets, whereas other clinical-chemical serum parameters (liver cell and muscle cell necrosis indicating enzymes, haemoglobin, haematocrit, magnesium, inorganic phosphate) were not influenced by increasing Fusarium toxin concentrations. 6. Supplementation of the diets with Mycofix Plus decreased performance in a manner independent of mycotoxin concentration. Moreover, some clinical-chemical serum parameters were significantly altered due to Mycofix Plus but also independently of the dietary mycotoxin concentration.
Collapse
Affiliation(s)
- S Dänicke
- Institute of Animal Nutrition, Federal Agricultural Research Centre, Braunschweig (FAL), Braunschweig, Germany.
| | | | | | | | | | | |
Collapse
|
39
|
Dänicke S, Ueberschär KH, Halle I, Matthes S, Valenta H, Flachowsky G. Effect of addition of a detoxifying agent to laying hen diets containing uncontaminated or Fusarium toxin-contaminated maize on performance of hens and on carryover of zearalenone. Poult Sci 2002; 81:1671-80. [PMID: 12455595 DOI: 10.1093/ps/81.11.1671] [Citation(s) in RCA: 95] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
16-wk experiment with laying hens was carried out to examine the effects of feeding of mycotoxin-contaminated maize (CM) on performance, nutrient digestibility, weight of organs, serum chemical parameters, and antibody titers to Newcastle disease virus (NDV) in serum. Also tested were fimbrien antigen K88 in egg yolk and zearalenone (ZON) residues in eggs and tissues. The Fusarium-toxin-contaminated maize contained 17,630 microg deoxynivalenol and 1,580 microg ZON/kg. Moreover, Mycofix Plus (MP), a so-called detoxifying agent, was added to both the uncontaminated control (UCM) and to the CM diet (70% dietary maize inclusion). Each of the four resulting diets (UCM, UCM-MP, CM, CM-MP) was tested on 25 laying hybrids (Lohmann Brown). Feeding of the CM diets significantly depressed feed intake compared to the control groups by approximately 5%. This was mainly due to the effects observed at the beginning of the experiment. Daily egg mass production/hen was 56.6, 58.4, 53.9, and 55.2 g in groups UCM, UCM-MP, CM and CM-MP, respectively. Nutrient digestibility and metabolizability of gross energy were slightly depressed by feeding the CM diets and improved by MP addition. Feeding of the CM diets resulted in a significant decrease in serum titers to NDV and to an increase in yolk titers to antigen K88. No residues of ZON or of its metabolites were found in yolk, albumen, abdominal fat, breast meat, follicles greater than 1 cm in diameter, ovaries including follicles smaller than 1 cm in diameter, magnum, and serum. ZON and alpha-zearalenol (alpha-ZOL) were detected in livers of hens fed the CM diets at mean concentrations of 2.1 and 3.7 microg/kg, respectively. It was concluded that feeding maize which was highly contaminated with Fusarium mycotoxins adversely influenced performance of hens and modulated immune response. At the given level of zearalenone and at the indicated detection limits, no residues of ZON and its metabolites were found in eggs. The effects of the tested detoxifying agent were quite mycotoxin-independent.
Collapse
Affiliation(s)
- S Dänicke
- Institute of Animal Nutrition, Federal Agricultural Research Centre, Braunschweig (FAL), Bundesallee 50, D-38116 Braunschweig, Germany.
| | | | | | | | | | | |
Collapse
|
40
|
Weigend S, Matthes S, Sölkner J, Lamont SJ. Resistance to Marek's disease virus in White Leghorn chickens: effects of avian leukosis virus infection genotype, reciprocal mating, and major histocompatibility complex. Poult Sci 2001; 80:1064-72. [PMID: 11495456 DOI: 10.1093/ps/80.8.1064] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Genetic improvement for resistance to Marek's Disease (MD) in chickens continues to be of interest to the poultry industry. The aims of this study were to identify effects of the MHC on the molecular level and of avian leukosis virus (ALV) resistance status on MD mortality in two noninbred White Leghorn chicken lines that differ in B blood group type. Previously, within each of the chicken lines, sublines had been selected for resistance or susceptibility to ALV infection with Subgroups A and B. In this study, F2 offspring, obtained by crossing the two ALV-resistant or the two ALV-susceptible sublines, were tested for MD mortality after contact exposure at 1 d of age. Reciprocal matings were made in the grandparental generation. The MD mortality percentages, in an observation period of 17 wk, of F2 offspring from two hatches were 82.63 and 92.35%, respectively. Survival analysis (Cox model) was applied to assess the risk of dying from MD. No differences in MD mortality risk profiles were found between ALV-resistant and ALV-susceptible F2 offspring. Within ALV-susceptible F2 offspring, however, a reciprocal mating effect was observed in both hatches. The MHC Class I, II, and IV restriction fragment length polymorphism (RFLP) analyses were carried out on birds of the first hatch. Although two of 11 MHC class IV RFLP bands displayed a significant effect, in general, a strong association of MHC and MD mortality was not detectable.
Collapse
Affiliation(s)
- S Weigend
- Institute for Animal Science and Animal Behavior, Federal Agriculture Research Center, Mariensee, Neustadt, Germany
| | | | | | | |
Collapse
|
41
|
Dänicke S, Ueberschär KH, Halle I, Matthes S, Valenta H, Flachowsky G. On the effects of Fusarium toxin contaminated maize in laying hen feeding. Mycotoxin Res 2001; 17 Suppl 1:62-6. [PMID: 23605762 DOI: 10.1007/bf03036714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The effects of feeding a Fusarium toxin contaminated maize (CM) to laying hens were studied in a 16-week lasting experiment. The CM contained 17630 μg deoxynivalenol (DON) and 1580 μg zearalenone (ZON) per kg.Animal performance, serum chemical parameters, antibody titers to Newcastle disease virus (NDV) in serum, antibody titers to fimbrien antigen K88 in egg yolk, and ZON residues in eggs and tissues were investigated.Moreover, Mycofix® Plus (MP), a so-called detoxifying agent, was added both the non-contaminated control (M) and to the CM diet. Each of the four resulting diets (M, M-MP, CM, CM-MP) was tested on 25 laying hybrids (Lohmann Brown).Hens fed the CM- and the CM-MP diet had a significantly depressed feed intake compared to the control groups of about 5 percent, mainly due to the effects observed at the beginning of the experiment.Daily egg mass production per hen was 56.6 g, 58.4 g, 53.9 g and 55.2 g in groups M, M-MP, CM and CM-MP, respectively. The main factors (maize contamination, MP-addition) were significant, whereas interactions were insignificant, suggesting a mycotoxin-independent effect of MP.Feeding of the CM-diets resulted in a significant decrease in serum titers to NDV and to an increase in yolk titers to antigen K88.No residues of ZON or of its metabolites were found in yolk, albumen, abdominal fat, breast meat, follicles greater than one cm in diameter, ovaries including follicles smaller than one cm in diameter, magnum or serum. ZON and α-zearalenol (α-ZOL) were detected in the livers of hens fed the CM-diets at mean concentrations of 2.1 μg/kg and 3.7 μg/kg, respectively.It was concluded that the feeding of maize highly contaminated with Fusarium mycotoxins adversely influenced performance of the hens and modulated immune response. At the given level of zearalenone and at the detection limits (0.5-2 μg/kg), no residues of ZON or its metabolites were found in eggs. The effects of the tested detoxifying agent were found to be independent of mycotoxins.
Collapse
Affiliation(s)
- S Dänicke
- Institute of Animal Nutrition, Federal Agricultural Research Centre, Braunschweig (FAL), Bundesallee 50, D-38116, Braunschweig, Germany
| | | | | | | | | | | |
Collapse
|
42
|
Fritsch G, Scharner D, Fröschl G, Buchinger P, Peters C, Matthes S, Witt V, Gadner H. Selection of CD34-Positive Blood Cells for Allogeneic Transplantation: Approaches to Optimize D34-Cell Recovery, Purity, Viability, and T-cell Depletion. Oncol Res Treat 2000; 23:449-456. [PMID: 11441240 DOI: 10.1159/000027219] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND: Methods for clinical-scale selection of CD34-positive hematopoietic stem and progenitor cells have facilitated allogeneic transplants using HLA-mismatched healthy donors. We examined different approaches to purify mobilized CD34+ cells, focusing on yield, purity, and viability of the selected cells and T-cell depletion levels. METHODS: Sixty-seven CD34-positive selections were performed for a total of 37 allogeneic transplantations, 23 of which from HLA-haploidentical donors. The selection devices were the Isolex((R)) 300i (v. 1.12) used alone (n =13) or with the SuperMACS (n = 29); the CliniMACS (n = 3); and the Isolex 300i (v. 2.0b1). The latter was used for CD34-positive selection (n = 7) and combined CD34+/CD4 8 19-negative selections (n =15). DNAse was included to reduce cell clumping. RESULTS: With the Isolex 300i (v. 1.12), the median CD34+-cell recovery increased from 51% (without DNAse) to 61% (15 mg DNAse) and 70% (7.5 mg). DNAse (5 mg) was used for 22 selections with the Isolex (v. 2.0b1) without cell clumping. CD34-positive cell purity, yield, and viability, as well as the degree of CD3 depletion varied with the selection device and procedure used. CONCLUSION: With regard to all of the above-mentioned parameters, the best results were obtained with the Isolex 300i (v. 2.0b1). Values achieved for CD34-positive cells were 98% for purity, 50-60% for yield, and > 96% for cell viability; T-cell depletion was 4.5 to > 5 log. The automated and closed system provides target cells that are free of both magnetic particles and murine monoclonal antibody. Copyright 2000 S. Karger GmbH, Freiburg
Collapse
Affiliation(s)
- G. Fritsch
- Forschungsinstitut für krebskranke Kinder, Wien
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, Jones RB. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biol Blood Marrow Transplant 2000; 6:198-203. [PMID: 10816028 DOI: 10.1016/s1083-8791(00)70043-7] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
We retrospectively evaluated 443 breast cancer patients treated with high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) with autologous stem cell support to characterize the cardiac toxicity of this regimen. Patients had stage II-III (n = 243) or stage IV (n = 200) breast cancer. We observed an overall 5.1% incidence of cardiac complications, both clinical and subclinical, in the whole group: 4.9% in stage II-III and 5.5% in stage IV patients. Clinical cardiomyopathy (CMP) was observed in 1.6% of stage II-III patients (1 case of fatal grade 5 toxicity and 3 cases of grade 3 CMP) and in 3.5% of patients with stage IV disease (1 case of grade 4 and 6 cases of grade 3). The incidence of cardiac toxicity did not differ significantly between the groups. Prior radiation therapy to the mediastinum or left chest wall (P = .001) and advanced age (P = .01) were independent predictors of an increased risk of the appearance of this complication. No pharmacodynamic correlation was observed between any of the 3 drugs and cardiac toxicity.
Collapse
Affiliation(s)
- Y Nieto
- University of Colorado Bone Marrow Transplant Program, Denver 80262, USA.
| | | | | | | | | | | |
Collapse
|
44
|
Dubovsky J, Daxberger H, Fritsch G, Printz D, Peters C, Matthes S, Gadner H, Lion T, Muller-Bérat N. Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia 1999; 13:2059, 2060-9. [PMID: 10602430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
The monitoring of chimerism by PCR has become a routine diagnostic approach in patients after allogeneic bone marrow or peripheral blood stem cell transplantation. Nevertheless, a temporal correlation between molecular and hematologic assessment of engraftment has not been clearly established. To address this issue, and to determine the potential clinical implications of early kinetics of mixed chimerism, we have investigated 66 allogeneic stem cell transplantations (SCTs) in 58 pediatric patients suffering from different types of leukemia (n = 44) or non-malignant hematologic disorders (n = 14) by close molecular monitoring during the first days and weeks after transplantation. Patient- and donor-derived hematopoiesis were assessed at 1- to 3-day intervals in peripheral blood samples by PCR analysis of highly polymorphic microsatellite loci (STR-PCR). Detection of an increasing, and ultimately dominant donor-specific allelic pattern, which we defined as molecular engraftment, preceded hematologic engraftment by a median of 7 days (range 1-17 days) in all patients investigated. PCR analyses during the first days after transplantation facilitated detection of molecular engraftment according to the above definition by day +14 (range day +2 to day +14), thus permitting prediction of successful engraftment (upper limit of the two-sided confidence interval po = 6%) while the peripheral leukocyte counts were mostly below 200/microl. In three cases, however, the criteria for molecular engraftment were not fulfilled by day +14. These patients also failed to show hematologic engraftment, and required a second transplantation. Close monitoring by STR-PCR showed that graft rejection and autologous recovery can occur early and with very rapid dynamics. Molecular analysis of specific leukocyte subsets isolated by flow-sorting enabled sensitive assessment of changes in the pattern of chimerism which had escaped detection in assays using whole white blood cell (WBC) samples. This approach facilitated the identification of expanding or decreasing recipient cells, and permitted early detection of impending rejection or relapse. Moreover, monitoring of the dynamics of chimerism allowed rapid assessment of the response to therapy. Our observations provide support for the concept of initiating genotype analyses early after SCT and monitoring at rather short intervals to permit timely evaluation of clinically relevant processes, and to provide a basis for early implementation of treatment.
Collapse
Affiliation(s)
- J Dubovsky
- St Anna Children's Hospital, Vienna, Austria
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Nieto Y, Cagnoni PJ, Shpall EJ, Matthes S, Barón A, Jones RB, Bearman SI. Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res 1999; 5:1731-7. [PMID: 10430076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
The purpose of this study was to assess the efficacy of high-dose chemotherapy (HDC) with autologous stem cell transplant in stage IV breast cancer patients with minimal metastases. Eligible patients had (a) disease that could be resected en bloc and/or irradiated with curative intent using a single field and could, thus, be rendered as having no evidence of disease (NED); and/or (b) <5% bone marrow involvement. From September 1991 to August 1997, 40 consecutive patients were prospectively entered on the study. Pre-HDC local treatment consisted of surgery (n = 31) and radiotherapy (XRT; n = 3). All patients received HDC with cyclophosphamide, cisplatin, and 1,3-bis(2-chloroethyl)-1-nitrosourea and autologous stem cell transplant, with or without CD34 selection. Following HDC, 22 patients received XRT. Four patients died of treatment-related complications. Eighteen patients developed grade 3 nonhematological toxicities (15 lung, 2 cardiomyopathy, and 1 optic neuritis), which resolved with therapy. Within a median follow-up of 49 (15-91) months, 14 patients had relapsed. Twenty-five patients (62.5%) were alive, and 22 patients (55%) were alive and free of disease. Median event-free and overall survivals were 43 and 77 months, respectively. In the subset of patients with one metastatic site, 17 of 24 (68%) remained relapse free. Grade 2 tumors, a single metastatic site, and delivery of XRT were favorable predictors of relapse-free survival in univariate but not multivariate analyses. Inclusion of HDC, as described, in the multimodal treatment of stage IV breast cancer patients with minimal metastases is promising. These results warrant prospective randomized trials with a HDC-containing arm in this patient population.
Collapse
Affiliation(s)
- Y Nieto
- University of Colorado Bone Marrow Transplant Program, Denver 80262, USA.
| | | | | | | | | | | | | |
Collapse
|
46
|
Cagnoni PJ, Matthes S, Day TC, Bearman SI, Shpall EJ, Jones RB. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999; 24:1-4. [PMID: 10435726 DOI: 10.1038/sj.bmt.1701832] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Interpatient variability in exposure to certain chemotherapy agents can influence patient outcome, particularly with high-dose chemotherapy. We evaluated the possibility of a pharmacokinetic (PK) drug-drug interaction between the antiemetic agents and high-dose cyclophosphamide, cisplatin and BCNU (CPA/cDDP/BCNU). Twenty-three self-selected patients treated with high-dose CPA/cDDP/BCNU followed by autologous hematopoietic progenitor cell support (AHPCS) received ondansetron, lorazepam and diphenhydramine as antiemetics. PK parameters for each chemotherapeutic drug in the regimen were compared with those of 129 patients who received exactly the same chemotherapy but an antiemetic regimen substituting prochlorperazine for ondansetron. In addition, we performed a review of the English literature for reported drug-drug interactions between antiemetics and chemotherapy agents that led to modifications in any PK parameters of the chemotherapy agent. Our retrospective study showed that the mean area under the curve (AUC) for both cyclophosphamide (76,600 vs 90,600 microg/ml/min, P=0.001) and cisplatin (525 vs 648 microg/ml/min, P = 0.01) were significantly lower in the ondansetron group when compared with the prochlorperazine group. The AUC for BCNU was not significantly different in both groups (544 vs 677, P = 0.43). We found only one report of modifications of the PK parameters of high-dose chemotherapy agents due to drug-drug interactions with the most commonly used antiemetics in a review of the English literature between 1966 and 1995. We concluded that the AUC of high-dose cyclophosphamide and cisplatin are significantly lower when ondansetron, as opposed to prochlorperazine, is used as the antiemetic. The small sample size and heterogeneity of this group of patients precludes any outcome analysis of pharmacodynamic endpoints such as toxicity or antitumor effect. Nevertheless, the potential for interactions between antiemetics and chemotherapy agents should be taken into account when using different high-dose chemotherapy regimens.
Collapse
Affiliation(s)
- P J Cagnoni
- University of Colorado Bone Marrow Transplant Program, University of Colorado Cancer Center, Denver, USA
| | | | | | | | | | | |
Collapse
|
47
|
Nieto Y, Xu X, Cagnoni PJ, Matthes S, Shpall EJ, Bearman SI, Murphy J, Jones RB. Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. Clin Cancer Res 1999; 5:747-51. [PMID: 10213208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Our objective was to assess whether the total area under the curve (AUC) of high-dose cyclophosphamide (CPA), combined with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea, could be predicted from its AUC on the first day of treatment. We reviewed the AUC of CPA in 470 patients who underwent pharmacokinetic monitoring of the drug. All patients received the same high-dose regimen of CPA, cisplatin, and 1,3-bis(2-chloroethyl)-1-nitrosourea (STAMP-I) with identical antiemetic support. Subsequently, patients who experienced a toxic death, relapsed after high-dose chemotherapy, or remained relapse-free at a minimum follow-up of 1 year after high-dose chemotherapy were analyzed for a correlation between the total AUC of CPA and both relapse-free survival and toxic death. The AUC of CPA decreased from day 1 to day 2 in most patients. However, its changes from day 2 to day 3 varied significantly. Neither the value of AUC on day 1 nor its decreasing trend from day 2 to day 3 could predict the AUC on day 3 and the total AUC. Our pharmacodynamic analysis in 335 patients failed to show a correlation between the total AUC of CPA and either toxic death or relapse-free survival. The significant intersubject variability in the AUC of CPA makes the final AUC of the drug unpredictable from an initial measurement on day 1. Thus, in this combination, measurement of levels of parent CPA, with the objective of real-time therapeutic monitoring of this drug, is not informative.
Collapse
Affiliation(s)
- Y Nieto
- University of Colorado Bone Marrow Transplant Program, Denver 80262, USA.
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, DeBoom T, Barón A, Jones RB. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res 1999; 5:501-6. [PMID: 10100699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
The purpose of this study was to describe acute encephalopathy as a new toxicity associated with paclitaxel, when it is delivered at high doses (> or =600 mg/m2) with stem cell support. A total of 129 patients, included in clinical trials of paclitaxel-containing high-dose chemotherapy, were analyzed. A total of 114 patients received paclitaxel at a dose of > or =600 mg/m2. Six patients presented acute encephalopathy starting between 7 and 23 days after paclitaxel treatment; two of them had received prior whole-brain irradiation. Paclitaxel was given alone (one patient), with cyclophosphamide and cisplatin (two patients), and with cyclophosphamide and cisplatin plus 1,3-bis(2-chloroethyl)-1-nitrosourea (three patients). Central nervous system toxicity consisted of rapid obtundation and coma (five patients) and severe confusional picture with paranoid ideations (one patient). Brain magnetic resonance imaging showed diffuse white matter atrophy (one patient) or multiple small infarcts (one patient), or it was normal (four patients). Other complementary tests, including cerebrospinal fluid analysis and electroencephalography, were nondiagnostic. An effect from concomitant psychotropic medications or from other organ toxicities was excluded in all patients. Three patients recovered after 8-15 days, either spontaneously (two patients) or after high-dose steroids (one patient). Three patients died of irreversible coma. Necropsy, performed in two patients, showed generalized white matter atrophy and multiple brain parenchymal infarcts, respectively. No pharmacodynamic correlation between the occurrence of encephalopathy and a pharmacokinetic parameter of paclitaxel could be identified. Paclitaxel-containing high-dose chemotherapy can cause severe acute encephalopathy. An aggravating effect from prior brain irradiation or concurrent 1,3-bis(2-chloroethyl)-1-nitrosourea seems possible.
Collapse
Affiliation(s)
- Y Nieto
- University of Colorado Bone Marrow Transplant Program, University of Colorado, Denver 80262, USA.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Cagnoni PJ, Nieto Y, Shpall EJ, Bearman SI, Barón AE, Ross M, Matthes S, Dunbar SE, Jones RB. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol 1998; 16:1661-8. [PMID: 9586876 DOI: 10.1200/jco.1998.16.5.1661] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To evaluate the feasibility of high-dose chemotherapy (HDC) with autologous hematopoietic progenitor-cell support (AHPCS) as part of combined modality therapy (CMT) in patients with inflammatory breast cancer (IBC). PATIENTS AND METHODS From April 1993 to March 1997, 30 patients with IBC were treated at our program. Twenty-three patients received neoadjuvant chemotherapy (NAC) before HDC; 18 patients also received adjuvant chemotherapy following surgery, but before HDC. All patients received HDC with high-dose cyclophosphamide, cisplatin, and carmustine (BCNU) with AHPCS. Every patient underwent surgery either before (27 patients) or after (three patients) HDC. Patients received radiotherapy after HDC in addition to tamoxifen if their tumors were estrogen receptor-positive. RESULTS Thirteen patients experienced grade 3 or 4 nonhematologic noninfectious toxicities. In 12 patients (40%), this represented drug-induced lung injury, which in all cases responded to a 10-week course of corticosteroids. The only treatment-related death was secondary to hemolytic-uremic syndrome (HUS). Another patient suffered grade 4 CNS toxicity, which was completely reversible. All patients engrafted promptly. Eight patients relapsed, five of whom had a poor pathologic response to NAC. Relapses were local (five patients), local plus systemic (one), or systemic only (two). Median follow-up time from diagnosis and HDC is 23.5 (range, 7 to 49) and 19 (range, 4 to 44) months, respectively. Twenty-one patients (70%; 95% confidence interval [CI], 51% to 86%) remain alive and free of disease 4 to 44 months after HDC. Median disease-free survival (DFS) and overall survival have not yet been reached. CONCLUSION HDC as part of CMT is feasible in patients with IBC. The toxicity of this treatment program is significant, but tolerable. Despite the short follow-up duration, the promising DFS observed in this group of patients warrants randomized studies that include a HDC-containing arm in patients with IBC.
Collapse
Affiliation(s)
- P J Cagnoni
- Bone Marrow Transplant Program and Department of Preventive Medicine and Biometrics, University of Colorado Health Sciences Center, Denver 80262, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Cagnoni PJ, Shpall EJ, Bearman SI, Matthes S, Ross M, Taffs S, Jones RB. Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience. Semin Oncol 1996; 23:43-8. [PMID: 8996598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is one of the most important antineo-plastic agents developed over the last 20 years. It has proven activity in breast cancer, ovarian cancer, and non-small cell lung cancer. In this study, the possibility of incorporating paclitaxel into a high-dose chemotherapy regimen targeting patients with breast cancer was evaluated. From a widely used regimen composed of cyclophosphamide, cisplatin, and carmustine, carmustine was deleted and paclitaxel added at the beginning of the regimen. The dose of paclitaxel was then escalated until life-threatening toxicities occurred. It was demonstrated that the dose of paclitaxel could be escalated to 775 mg/m2, combined with cyclophosphamide 5,625 mg/m2 and cisplatin 165 mg/m2, followed by autologous hematopoietic progenitor cell support. A phase II study testing this combination in patients with chemotherapy-responsive metastatic breast cancer has been initiated. A new phase I study to test the feasibility of adding carmustine to this paclitaxel-based regimen is currently under way. The status of this study is briefly summarized.
Collapse
Affiliation(s)
- P J Cagnoni
- University of Colorado Bone Marrow Transplant Program, University of Colorado Cancer Center, Denver, USA
| | | | | | | | | | | | | |
Collapse
|